- BioLife Solutions press release ( NASDAQ: BLFS ): Q3 GAAP EPS of -$0.23 misses by $0.06 .
- Adjusted net loss (non-GAAP) for the third quarter of 2022 was $6.6 million compared with adjusted net loss of $8.3 million for the third quarter of 2021.
- Revenue of $40.7M (+20.4% Y/Y) misses by $1.36M .
- Total revenue for 2022 is now expected to range from $160 million to $164 million compared with prior guidance of $160 million to $166 million, and reflects year-over-year growth of 34% to 38% and organic growth of 37% to 40%.
- COVID-19 related revenue is expected to account for approximately 7% to 8% of total revenue.
For further details see:
BioLife Solutions GAAP EPS of -$0.23 misses by $0.06, revenue of $40.7M misses by $1.36M